Emerald Advisers’s Regeneron Pharmaceuticals REGN Stock Holding History

Emerald Advisers’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-357	Closed	-$375K	–	267
2024 Q3	$375K	Hold	357	–	–	0.01%	191
2024 Q2	$375K	Sell	357 -202	-36%	-$196K	0.02%	185
2024 Q1	$538K	Sell	559 -53	-9%	-$50.4K	0.02%	175
2023 Q4	$538K	Sell	612 -65	-10%	-$53.5K	0.02%	173
2023 Q3	$557K	Buy	677 +272	+67%	+$214K	0.03%	165
2023 Q2	$291K	Buy	+405	New	+$312K	0.01%	193
2020 Q4	–	Sell	-557	Closed	-$312K	–	337
2020 Q3	$312K	Buy	+557	New	+$338K	0.01%	206
2013 Q3	–	Sell	-4,368	Closed	-$982K	–	355
2013 Q2	$982K	Buy	+4,368	New	+$1.02M	0.06%	237

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Emerald Advisers's REGN Position: Q4 2024 in Review

Emerald Advisers sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 357 shares — an estimated $375K sold.

Emerald Advisers first reported a position in REGN in Q2 2013 and held it in 8 quarters. The position peaked at $982K in Q2 2013. 1,320 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

Emerald Advisers reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Emerald Advisers sold 357 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $375K.
Emerald Advisers first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 8 quarters.
Emerald Advisers's Regeneron Pharmaceuticals position peaked at $982K in Q2 2013.
1,320 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Emerald Advisers's 13F filing for Q4 2024, filed 11 Feb 2025.